



INSPIRED BY
OPPORTUNITY.
DRIVEN BY
KNOWLEDGE.

INSIGHT Volume 4, October - 2019

BIOCON LICENSES 3 GENERIC DRUGS TO CHINA MEDICAL SYSTEM HOLDINGS (CMS) INCREASING ITS TOTAL ADDRESSABLE MARKET BY USD 800 MILLION

Biocon recently signed a [10-year license & supply pact](#) with CMS to develop, manufacture and supply 3 generic products, which CMS will register and commercialize. This agreement extends Biocon's market reach to China, the 2nd largest pharma market in the world.

This move was made possible by the [recent changes in regulations](#) in China as part of a healthcare systems reform initiative. The Generics Quality Consistency evaluation system has increased access to high quality generic drugs throughout China. The Economic Times reports that [the Chinese market may soon open up for Indian Generics manufacturers](#), a move that will further spur generics industry growth.

As one of the early movers in this direction, Biocon has [added to its total addressable market](#) by USD 800 Million and has seen its [share price move up](#) after the announcement.

XERIS PHARMA GAINS USFDA APPROVAL FOR SHELF-STABLE GLUCAGON INJECTOR PEN TO TREAT SEVERE HYPOGLYCAEMIA

Xeris Pharmaceuticals [announced](#) that the USFDA has approved GVOKE a ready-to-use, room-temperature stable, liquid glucagon injectable to treat severe hypoglycaemia in paediatric and adult patients. GVOKE is the first glucagon product approved that can be administered via a prefilled syringe or auto-injector, vastly reducing the steps to prepare and administer glucagon in the event of severe hypoglycemia. This approval comes on the back of [results from three phase III clinical trials](#) that demonstrated 100% and 99% success rates in treating children and adults (respectively) for hypoglycaemia. [Severe hypoglycaemia](#) is characterized by dangerously low blood sugar levels and can lead to seizure, loss of consciousness or even death if untreated.

APPLE ANNOUNCES THREE UNPRECEDENTED HEALTHCARE STUDIES IN WOMEN'S HEALTH, HEART HEALTH & MOBILITY, AND HEARING

The [three studies](#) would [leverage data from Apple Watch](#) users (gained through the new Research app). Apple will partner with the National Institutes of Health, the American Heart Association, Harvard University's T.H. Chan School of Public Health and Brigham and Women's Hospital in Boston, and the University of Michigan on the studies. The Women's Health study will inform screening and risk assessment of conditions like polycystic ovary syndrome (PCOS), infertility, osteoporosis, pregnancy and menopausal transition. The Heart & Movement study will focus on heart rate and mobility signals — like walking pace and flights of stairs climbed — relate to hospitalizations, falls, heart health and quality of life in order to promote healthy movement and improved cardiovascular health. The Hearing study will collect data over time in order to understand how everyday sound exposure can impact hearing. These studies are poised to democratize health research, as well as provide rich data to researchers to improve human health.

ABOUT TAKE SOLUTIONS

TAKE Solutions delivers domain-intensive services in Life Sciences and Supply Chain Management.

In the fast-growing Life Sciences space, TAKE offers clients a unique combination of full-service Clinical, Regulatory and Safety services backed by unique technology expertise. Our range of services span from clinical trials to regulatory submissions to post-marketing safety, all backed by insights derived through proprietary industry networks forums. With a team of leading Life Sciences experts, best-in-class systems and processes, and bespoke, industry-specific technology and analytics, TAKE delivers successful outcomes for clients. Our global roster of clients includes large and small innovator biopharmaceutical companies as well as generics manufacturers.

With operations spread across North America, Europe, Asia, and South America, TAKE is a Public Company, listed in India on the Bombay Stock Exchange and the National Stock Exchange. Led by a team of industry stalwarts and domain experts, TAKE has been growing steadily with FY19 revenues touching INR 20,390 Mn (USD 292 Mn).

For more details, please visit www.takesolutions.com.

